News
An innovator in developing therapeutic antibodies, fusion proteins and circRNA
News
2026-03-09
Fapon Biopharma to Present Next-Generation CD3/TCR VHH TCE Platform at 19th Annual European Life Sciences CEO Forum
Read more 
2025-02-28
Fapon Biopharma Announces FDA Approval of IND for FP008, a First-in-Class Immunotherapy for Solid Tumors
Read more 
2025-01-07
Fapon Biopharma Introduces FP008 at Biotech Showcase: A Safer and More Effective Immunotherapy for Refractory Cancers
Read more
2024-06-04
Fapon Biopharma Announces a Safer Immunotherapy for Cancers
At Bio International Convention 2024, which is taking place here in San Diego during June 3-6, Fapon Biopharma, an innovator in developing therapeutic antibodies and fusion proteins, has announced an immunocytokine with modified IL-10M fused to anti-PD-1 antibody, codenamed FP008.
Read more
2024-03-25
Fapon and Stanford Healthcare Innovation Lab Co-Host Virtual Conference on RNA Delivery and Gene Editing Featuring Nobel Prize Winner
On March 20, the groundbreaking virtual conference "In Vivo Frontiers: The Promise and Progress of RNA Delivery & Gene Editing," hosted by the Stanford Healthcare Innovation Lab in collaboration with Fapon, took place successfully. Distinguished speakers, including Nobel Prize Winner Jennifer Doudna and renowned scientist Robert Langer, alongside other leading experts, presented in the event.
Read more
2023-10-18
Fapon Shares its Visionary Strategies at the Inaugural Innovative Diagnostics and Therapeutics Forum
Fapon, a leading life sciences company, announced its strategic plans in innovative diagnostics and therapeutics business at the inaugural Innovative Diagnostics and Therapeutics Forum in Suzhou, China, on 18 October 2023.
Read more
2023-02-22
Fapon Biopharma’s Anti-CD47 Antibody FP002 Earns IND Approval from FDA
(Feb. 22, 2023, Shenzhen, China) Fapon Biopharma, an innovative biotech company, announced today that its Investigational New Drug (IND) application of FP002.
Read more
